NYU Medical Center Partners with Rosetta Genomics to Develop a Line of Diagnostic Tools for Lung and mesothelioma Cancers
Source: Rosetta Genomics
The NYU Medical Center, one of the world's premier academic medical institutions, has partnered with Rosetta Genomics, a leader in the development of microRNA-based diagnostics and therapeutics, to jointly-develop early detection diagnostic tools for lung cancer and mesothelioma. Dr. Harvey Pass, Professor and Chief of the Division of Thoracic Surgery and Thoracic Oncology at NYU Medical Center, describes a test "... that will be able to detect cancer at an ealy stage using a simple blood draw...." The test will use a proprietary protocol developed by Rosetta Genomics to extract microRNAs, which are a recently-discovered form of RNAi that act as protein regulators and have shown promise as biomarkers for a variety of cancers.
The NYU Medical Center, one of the world's premier academic medical institutions, has partnered with Rosetta Genomics, a leader in the development of microRNA-based diagnostics and therapeutics, to jointly-develop early detection diagnostic tools for lung cancer and mesothelioma. Dr. Harvey Pass, Professor and Chief of the Division of Thoracic Surgery and Thoracic Oncology at NYU Medical Center, describes a test "... that will be able to detect cancer at an ealy stage using a simple blood draw...." The test will use a proprietary protocol developed by Rosetta Genomics to extract microRNAs, which are a recently-discovered form of RNAi that act as protein regulators and have shown promise as biomarkers for a variety of cancers.
Labels: lung cancer, mesothelioma
© Belluck & Fox, L.L.P. All rights reserved.
